{"id":"efmoroctocog-alfa","rwe":[{"pmid":"41850309","year":"2026","title":"In Vitro Stability Study Supports the Use of Efmoroctocog Alfa and Rurioctocog Alfa Pegol for Continuous Infusion in Hemophilia A.","finding":"","journal":"Seminars in thrombosis and hemostasis","studyType":"Clinical Study"},{"pmid":"40982238","year":"2025","title":"Clinical and Surgical Experiences with Efmoroctocog Alfa in Pediatric Population with Hemophilia A.","finding":"","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","studyType":"Clinical Study"},{"pmid":"40634274","year":"2025","title":"Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal.","finding":"","journal":"Expert review of pharmacoeconomics & outcomes research","studyType":"Clinical Study"},{"pmid":"40616274","year":"2025","title":"A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A.","finding":"","journal":"Hematology (Amsterdam, Netherlands)","studyType":"Clinical Study"},{"pmid":"40337622","year":"2025","title":"Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature.","finding":"","journal":"Research and practice in thrombosis and haemostasis","studyType":"Clinical Study"}],"tags":[{"label":"Biologic","category":"modality"},{"label":"Active","category":"status"},{"label":"Hereditary factor VIII deficiency disease","category":"indication"},{"label":"Swedish Orphan Biovitrum AB","category":"company"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1210.987,"date":"","count":276,"signal":"Haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 276 times (LLR=1211)"},{"llr":300.696,"date":"","count":38,"signal":"Factor VIII inhibition","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=301)"},{"llr":280.662,"date":"","count":51,"signal":"Haemarthrosis","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=281)"},{"llr":239.465,"date":"","count":36,"signal":"Traumatic haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=239)"},{"llr":191.63,"date":"","count":28,"signal":"Spontaneous haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=192)"},{"llr":117.978,"date":"","count":35,"signal":"Limb injury","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=118)"},{"llr":108.338,"date":"","count":33,"signal":"Joint injury","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=108)"},{"llr":106.652,"date":"","count":23,"signal":"Muscle haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=107)"}],"commonSideEffects":[{"effect":"Factor VIII inhibition","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Device-related thrombosis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Rash papular","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Dysgeusia","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Bradycardia","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Hot flush","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Lower abdominal pain","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Joint swelling","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Chest pain","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Feeling cold","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Feeling hot","drugRate":"0.4%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Myocardial infarction","drugRate":"0.7%","severity":"serious"},{"effect":"Angiopathy","drugRate":"0.4%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Swedish Orphan Biovitrum AB","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EFMOROCTOCOG ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:21:12.773481+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:21:24.334340+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:21:12.805059+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EFMOROCTOCOG ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:21:25.073568+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor VIII exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:25.869801+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297945/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:25.740850+00:00"}},"allNames":"elocta","offLabel":[],"synonyms":["eloctate","efmoroctocog alfa","elocta","efraloctocog alfa","BIIB031"],"timeline":[{"date":"2015-11-19","type":"positive","source":"DrugCentral","milestone":"EMA approval (Swedish Orphan Biovitrum AB)"}],"approvals":[{"date":"2015-11-19","orphan":false,"company":"Swedish Orphan Biovitrum AB","regulator":"EMA"}],"brandName":"Elocta","ecosystem":[{"indication":"Hereditary factor VIII deficiency disease","otherDrugs":[{"name":"desmopressin","slug":"desmopressin","company":"Ferring Pharms Inc"},{"name":"emicizumab","slug":"emicizumab","company":"Genentech Inc"},{"name":"vasopressin","slug":"vasopressin","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Elocta is a recombinant factor VIII Fc fusion protein, which means it's a genetically engineered version of the factor VIII protein that's attached to an Fc region, increasing its half-life and stability."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5178","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EFMOROCTOCOG%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EFMOROCTOCOG ALFA","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:53:00.825282","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:27.625499+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"efmoroctocog alfa","indications":{"approved":[{"name":"Hereditary factor VIII deficiency disease","source":"DrugCentral","snomedId":28293008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04293523","phase":"","title":"A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-03-30","conditions":["Hemophilia A"],"enrollment":427,"completionDate":"2026-07"},{"nctId":"NCT04690322","phase":"PHASE4","title":"POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-04-15","conditions":["Hemophilia A","Factor VIII"],"enrollment":28,"completionDate":"2027-07"},{"nctId":"NCT05856266","phase":"PHASE4","title":"An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa","status":"TERMINATED","sponsor":"Swedish Orphan Biovitrum","startDate":"2023-08-24","conditions":["Hemophilia A","Hemophilia B"],"enrollment":10,"completionDate":"2023-12-06"},{"nctId":"NCT02976753","phase":"","title":"Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2016-12","conditions":["Hemophilia A"],"enrollment":361,"completionDate":"2021-11-03"},{"nctId":"NCT03055611","phase":"","title":"A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-05-09","conditions":["Haemophilia A","Haemophilia B"],"enrollment":201,"completionDate":"2022-04-19"},{"nctId":"NCT03103542","phase":"PHASE4","title":"Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-08-29","conditions":["Hemophilia A"],"enrollment":16,"completionDate":"2020-08-31"},{"nctId":"NCT04728217","phase":"PHASE4","title":"Health Related Quality of Life of Youth and Young Adults With Haemophilia A","status":"COMPLETED","sponsor":"The League of Clinical Research, Russia","startDate":"2021-04-15","conditions":["Hemophilia A"],"enrollment":30,"completionDate":"2023-02-20"},{"nctId":"NCT04303559","phase":"PHASE3","title":"The Hemophilia Inhibitor Prevention Trial","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2021-10-11","conditions":["Hemophilia A Without Inhibitor"],"enrollment":1,"completionDate":"2022-06-16"},{"nctId":"NCT04303572","phase":"PHASE3","title":"The Hemophilia Inhibitor Eradication Trial","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2021-11-01","conditions":["Hemophilia A With Inhibitor"],"enrollment":1,"completionDate":"2022-06-27"},{"nctId":"NCT02234323","phase":"PHASE3","title":"An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2015-01-12","conditions":["Hemophilia A"],"enrollment":108,"completionDate":"2019-09-23"},{"nctId":"NCT03093480","phase":"PHASE4","title":"A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2017-12-08","conditions":["Hemophilia A With Inhibitors"],"enrollment":16,"completionDate":"2021-02-16"},{"nctId":"NCT02546622","phase":"","title":"ATHN 2: Factor Switching Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2015-09","conditions":["Hemophilia"],"enrollment":310,"completionDate":"2020-06-30"},{"nctId":"NCT02083965","phase":"PHASE1","title":"Pharmacokinetics of rFVIIIFc at Two Vial Strengths","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2014-03","conditions":["Severe Hemophilia A"],"enrollment":19,"completionDate":"2015-05"},{"nctId":"NCT01458106","phase":"PHASE3","title":"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2012-11","conditions":["Hemophilia A"],"enrollment":71,"completionDate":"2013-12"},{"nctId":"NCT02502149","phase":"PHASE3","title":"Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2015-08","conditions":["Severe Hemophilia A"],"enrollment":24,"completionDate":"2017-06"},{"nctId":"NCT01454739","phase":"PHASE3","title":"Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2011-12","conditions":["Hemophilia A"],"enrollment":240,"completionDate":"2017-10"},{"nctId":"NCT02392156","phase":"","title":"Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes","status":"TERMINATED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2015-07","conditions":["Hemophilia A","Hemophilia B"],"enrollment":3,"completionDate":"2015-12"},{"nctId":"NCT02586012","phase":"PHASE2","title":"Weight-based Dosing in Hemophilia A","status":"TERMINATED","sponsor":"Craig Seaman","startDate":"2015-09","conditions":["Hemophilia"],"enrollment":30,"completionDate":"2020-01-10"},{"nctId":"NCT03272568","phase":"EARLY_PHASE1","title":"Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-02-14","conditions":["Hemophilia","Menstrual Flow Excessive"],"enrollment":3,"completionDate":"2019-12-31"},{"nctId":"NCT02196207","phase":"PHASE3","title":"Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform","status":"WITHDRAWN","sponsor":"Margaret Ragni","startDate":"2020-08","conditions":["Severe Hemophilia A"],"enrollment":0,"completionDate":"2027-07"},{"nctId":"NCT03248141","phase":"","title":"Understanding Hemophilia A and B Drug Dosage Administration Patterns","status":"TERMINATED","sponsor":"Pfizer","startDate":"2017-09-01","conditions":["Hemophilia A","Hemophilia B"],"enrollment":11,"completionDate":"2018-03-14"},{"nctId":"NCT03405337","phase":"","title":"Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-14","conditions":["Hemophilia A"],"enrollment":160,"completionDate":"2018-06-13"}],"_emaApprovals":[{"date":"2015-11-19","status":"Authorised","company":"Swedish Orphan Biovitrum AB"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"30674","NDDF":"015552","UNII":"7PCM518YLR","INN_ID":"9680","RXNORM":"1543089","UMLSCUI":"C3834170","chemblId":"CHEMBL4297945","ChEMBL_ID":"CHEMBL4297945","KEGG_DRUG":"D10539","DRUGBANK_ID":"DB11607","SNOMEDCT_US":"718943005","MESH_SUPPLEMENTAL_RECORD_UI":"C587014"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Swedish Orphan Biovitrum AB","relationship":"Original Developer"}],"publicationCount":49,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"originalDeveloper":"Swedish Orphan Biovitrum AB","recentPublications":[{"date":"2026 Mar 18","pmid":"41850309","title":"In Vitro Stability Study Supports the Use of Efmoroctocog Alfa and Rurioctocog Alfa Pegol for Continuous Infusion in Hemophilia A.","journal":"Seminars in thrombosis and hemostasis"},{"date":"2025 Jan-Dec","pmid":"40982238","title":"Clinical and Surgical Experiences with Efmoroctocog Alfa in Pediatric Population with Hemophilia A.","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis"},{"date":"2025 Dec","pmid":"40634274","title":"Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal.","journal":"Expert review of pharmacoeconomics & outcomes research"},{"date":"2025 Dec","pmid":"40616274","title":"A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A.","journal":"Hematology (Amsterdam, Netherlands)"},{"date":"2025 Mar","pmid":"40337622","title":"Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature.","journal":"Research and practice in thrombosis and haemostasis"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Swedish Orphan Biovitrum AB","companyId":"swedish-orphan-biovitrum-ab","modality":"Recombinant protein","firstApprovalDate":"2015","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:27.625499+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}